Literature DB >> 1778174

Plasma steroid-binding proteins.

W Rosner1.   

Abstract

Two steroid-binding proteins circulate in plasma, corticosteroid-binding globulin and sex hormone-binding globulin. They both have several different but connected, physiologic functions. Each is the major determinant of the concentration of the physiologically important hormones that they bind. CBG regulates the concentration of free cortisol and progesterone, and SHBG regulates the concentration of free testosterone, dihydrotestosterone, and, to a lesser extent, estradiol. It is this small free fraction of the appropriate hormone that is the active principal in affecting hormone action. In the past few years, it has been shown that both of these proteins have high affinity, specific receptors on the plasma membranes of a variety of cells. It has also been shown that when SHBG's binding sites are occupied it cannot bind to its receptor; only unliganded SHBG can. There are, as yet, no published reports on the control of CBG binding by steroids. For both SHBG and CBG, if an appropriate steroid is present when the binding protein is itself bound to its receptor, rapid induction of adenylate cyclase activity and the accumulation of intracellular cAMP occur. Finally, CBG has been shown to be a member of the superfamily of serine proteinase inhibitors. When it is exposed to a serine protease, it is cleaved and release all, or most, of its bound cortisol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1778174

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  20 in total

1.  SHBG, plasma, and urinary androgens in weight lifters after a strength training.

Authors:  Marcos Maynar; Rafael Timon; Alfredo González; Guillermo Olcina; Fermin Toribio; Juan I Maynar; Maria J Caballero
Journal:  J Physiol Biochem       Date:  2010-06-09       Impact factor: 4.158

2.  Initial observations regarding free cortisol quantification logistics among critically ill children.

Authors:  Jerry J Zimmerman; Ruth M Barker; Rhona Jack
Journal:  Intensive Care Med       Date:  2010-08-19       Impact factor: 17.440

3.  Association of rs6259 polymorphism with SHBG levels and Poly Cystic Ovary Syndrome in Indian population: a case control study.

Authors:  Richa Bhatnager; Alka Senwal; Smiti Nanda; Amita S Dang
Journal:  Mol Biol Rep       Date:  2019-02-04       Impact factor: 2.316

4.  Physical activity and sex hormone levels in estradiol- and placebo-treated postmenopausal women.

Authors:  Farzana Choudhury; Leslie Bernstein; Howard N Hodis; Frank Z Stanczyk; Wendy J Mack
Journal:  Menopause       Date:  2011-10       Impact factor: 2.953

Review 5.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

Review 6.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

7.  Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women.

Authors:  Roksana Karim; Howard N Hodis; Frank Z Stanczyk; Rogerio A Lobo; Wendy J Mack
Journal:  J Clin Endocrinol Metab       Date:  2007-10-09       Impact factor: 5.958

8.  Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition.

Authors:  Samar R El Khoudary; Rachel P Wildman; Karen Matthews; Rebecca C Thurston; Joyce T Bromberger; Kim Sutton-Tyrrell
Journal:  Atherosclerosis       Date:  2012-08-18       Impact factor: 5.162

Review 9.  Adrenal insufficiency in patients with decompensated cirrhosis.

Authors:  Apostolos Ka Karagiannis; Theodora Nakouti; Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2015-05-18

10.  Model-based therapeutic correction of hypothalamic-pituitary-adrenal axis dysfunction.

Authors:  Amos Ben-Zvi; Suzanne D Vernon; Gordon Broderick
Journal:  PLoS Comput Biol       Date:  2009-01-23       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.